Transformative startups in Next-Gen Diagnostics & Lab Automation
Pitching session summary

Discover the future of biotech as startups push the boundaries of diagnostics, lab automation, analytics and drug discovery. This session will feature groundbreaking technologies transforming disease detection, laboratory sciences and the way therapies are developed. Presenters will explore innovations in single-particle dispension, real-time immunoassays, VR-powered diagnostics, next-gen allergy testing, precision medicine driven by biomarker insights, solutions advancing light-dependent biological techniques and novel approaches to accelerating drug development. Join experts and investors as they explore how these technologies are reshaping the landscape of healthcare and biotech.

Date, time and room information

May 6, 12:15-13:00, room Marriott 3+4+5

Moderation
Name Position Institution
Samantha Paoletti Head of Research and BD Life Science Technologies CSEM
Pitching companies
Company name Pitcher Title of presentation Link to company website
OptoLumina Thomas Höhener, CEO of OptoLumina AG The Lumiplate – A Multiwell Plate Lighting Device to Illuminate Biotech https://optolumina.com/
Bioscibex Chloé Albietz, CEO Changing the way we make drugs https://bioscibex.com/
SEED BIOSCIENCES Maxence Vieux-Rochas Accelerate time-to-market of biologics with novel impedance-based pipetting tools for precision 2D and 3D biology https://seedbiosciences.com/
Atanis Biotech Erwan Eriau, COO Bringing Allergy diagnostics in the era of biotechnology https://www.atanis-biotech.com/
Elionova Bruno Oesch, CEO and CSO One-step Real-time Immunoassays in 10 min: the ElioDX™ technology https://www.elionova.com/
Xemperia Sarah Cattin, CTO A revolution in early breast cancer detection: a blood test to save lives https://xemperia.com/
MachineMD Dominic Senn, CEO Opportunity in AI-Powered Brain Health https://www.machinemd.com/
Jury members
Name Position Institution
Bernard Spycher Board Member SVDI
Miro Venturi President Diamante Healthcare Consulting Sagl
Cédric Barra Senior Investment Manager Life Sciences OCCIDENT
Steffen Ehrhadt VP Investor Community, Partnerships and Sustainability SICTIC
Swiss Biotech Association